STAT+: Roche ends Huntington’s gene-silencing programs

Roche's decision to halt its gene-silencing programs for Huntington's disease signals a significant shift in the biotech industry's approach to tackling genetic disorders. This move comes as ARPA-H, a federal agency, ramps up its efforts to develop bespoke gene therapies, prompting other major players like Lilly and Novo Nordisk to push forward with their own initiatives under the Bridge program. Roche's withdrawal underscores the challenges and uncertainties in gene therapy research, highlighting the need for sustained innovation and investment in this promising but complex field. This shake-up could reshape the landscape of genetic disorder treatments and influence future research directions.